• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

Lupin receives FDA approval for generic Wellbutrin XL tabs

financialexpressApril 11, 2017

Tag: FDA , lupin

Lupin received approval for its Bupropion Hydrochloride Extended-Release tablets USP (XL), 150 mg and 300 mg from the US FDA to market a generic version of Wellbutrin XL tablets, 150 mg and 300 mg.

Lupin’s Bupropion Hydrochloride Extended-Release tablets USP (XL), 150 mg and 300 mg are the AB rated generic equivalent of Valeant Pharmaceuticals North America’s Wellbutrin XL tablets, 150 mg and 300 mg. It is indicated for the treatment of Major Depressive Disorder (MDD) and prevention of Seasonal Affective Disorder (SAD) in adults.

Wellbutrin XL tablets had US sales of $755 million according to IMS MAT December 2016.

Previous:World Homeopathy Day concludes successfully in Delhi

Next:Glenmark receives ANDA approval for Fenofibrate caps

Related News

Sartorius Stedim Biotech Opens New Center for Bioprocess Innovation in Marlborough, USA

PharmaSourcesNovember 22, 2024

Sartorius Stedim Biotech, a leading partner of the biopharmaceutical industry, today opened its new Center for Bioprocess Innovation in Marlborough, Massachusetts.

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

Lupin receives FDA approval for generic Wellbutrin XL tabs | Pharmasources.com

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Discover how AI in pharmacovigilance improves drug safety by predicting risks, identifying harmful interactions, and enhancing patient outcomes.

You may like
More>>

Thiophosphoramide (FDA)

Thiophosphoramide (FDA)
Medroxyprogesterone Acetate(FDA)

Medroxyprogesterone Acetate(FDA)
Deltamine (FDA)

Deltamine (FDA)
Vitamine B12 (FDA)

Vitamine B12 (FDA)
Mesnaum (FDA)

Mesnaum (FDA)
Prednisolone (FDA /COS)

Prednisolone (FDA /COS)
Deoxycyline (FDA)

Deoxycyline (FDA)
Ramantadine( FDA)

Ramantadine( FDA)
99% up, DMF, FDA (zero defect) Emtricitabine 143491-57-0

99% up, DMF, FDA (zero defect) Emtricitabine 143491-57-0
Simvastatin (FDA)

Simvastatin (FDA)

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service